The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarin
RG Pertwee - British journal of pharmacology, 2008 - Wiley Online Library
Cannabis sativa is the source of a unique set of compounds known collectively as plant
cannabinoids or phytocannabinoids. This review focuses on the manner with which three of …
cannabinoids or phytocannabinoids. This review focuses on the manner with which three of …
CB2: a cannabinoid receptor with an identity crisis
CB2 was first considered to be the 'peripheral cannabinoid receptor'. This title was bestowed
based on its abundant expression in the immune system and presumed absence from the …
based on its abundant expression in the immune system and presumed absence from the …
CB2 receptor in microglia: the guardian of self-control
JA Komorowska-Müller, AC Schmöle - International journal of molecular …, 2020 - mdpi.com
Microglia are key to maintaining the homeostasis of the brain. These immune cells of the
brain can be our biggest ally in fighting infections, but can worsen pathology or hinder …
brain can be our biggest ally in fighting infections, but can worsen pathology or hinder …
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
RG Pertwee - British journal of pharmacology, 2009 - Wiley Online Library
Mandarin translation of abstract Medicines that activate cannabinoid CB1 and CB2 receptor
are already in the clinic. These are Cesamet®(nabilone), Marinol®(dronabinol; Δ9 …
are already in the clinic. These are Cesamet®(nabilone), Marinol®(dronabinol; Δ9 …
Obesity: Current and potential pharmacotherapeutics and targets
V Narayanaswami, LP Dwoskin - Pharmacology & therapeutics, 2017 - Elsevier
Obesity is a global epidemic that contributes to a number of health complications including
cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders …
cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders …
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain
J Guindon, AG Hohmann - British journal of pharmacology, 2008 - Wiley Online Library
Cannabinoids suppress behavioural responses to noxious stimulation and suppress
nociceptive transmission through activation of CB1 and CB2 receptor subtypes. CB1 …
nociceptive transmission through activation of CB1 and CB2 receptor subtypes. CB1 …
Cannabis-based medicines and pain: a review of potential synergistic and entourage effects
U Anand, B Pacchetti, P Anand… - Pain management, 2021 - Taylor & Francis
The recent legalization of medicinal cannabis in several jurisdictions has spurred the
development of therapeutic formulations for chronic pain. Unlike pure delta-9 …
development of therapeutic formulations for chronic pain. Unlike pure delta-9 …
Cannabinoid receptor 2 signaling in neurodegenerative disorders: from pathogenesis to a promising therapeutic target
As a consequence of an increasingly aging population, the number of people affected by
neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and …
neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and …
An overview of the cannabinoid type 2 receptor system and its therapeutic potential
B Bie, J Wu, JF Foss, M Naguib - Current Opinion in …, 2018 - journals.lww.com
An overview of the cannabinoid type 2 receptor system and it... : Current Opinion in
Anesthesiology An overview of the cannabinoid type 2 receptor system and its therapeutic …
Anesthesiology An overview of the cannabinoid type 2 receptor system and its therapeutic …
Cannabinoids and pain: sites and mechanisms of action
K Starowicz, DP Finn - Advances in Pharmacology, 2017 - Elsevier
The endocannabinoid system, consisting of the cannabinoid 1 receptor (CB 1 R) and
cannabinoid 2 receptor (CB 2 R), endogenous cannabinoid ligands (endocannabinoids) …
cannabinoid 2 receptor (CB 2 R), endogenous cannabinoid ligands (endocannabinoids) …